FDA Mandates Boxed Warning Updates for JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Across All Approved Indications

Labeling compliance obligations for Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) have been materially expanded following an FDA review of a large randomized safety trial, with the agency now requiring revised Boxed Warnings covering serious cardiovascular events, malignancy, thrombosis, and death across all three JAK inhibitors.

The safety signal originates from a completed post-marketing trial comparing tofacitinib against TNF blockers in rheumatoid arthritis patients. Final results confirmed elevated risk of blood clots and death at both the lower and higher tofacitinib doses, a broader finding than the earlier 2019 and February 2021 Drug Safety Communications, which flagged the higher dose only. Because baricitinib and upadacitinib share the same mechanism of action and have not been evaluated in comparable large-scale safety trials, FDA is applying the same Boxed Warning revisions to those products on a class-wide basis.

Beyond labeling language, the agency is restricting all approved uses of the three products to patients who have not responded to, or cannot tolerate, one or more TNF blockers. For regulatory affairs teams, this use restriction carries direct consequences for approved indications language, Risk Evaluation and Mitigation Strategy (REMS) considerations, and any promotional materials referencing current prescribing information. Prescribing information revisions extend beyond the Boxed Warning to multiple body sections and the patient Medication Guide, requiring coordinated updates across labeling, medical affairs, and commercial functions.

Two other approved JAK inhibitors, Jakafi (ruxolitinib) and Inrebic (fedratinib), are not subject to these specific revisions; both are indicated for hematologic disorders and are receiving separate, distinct prescribing information updates. Manufacturers of those products should confirm the scope of required changes independently through Drugs@FDA.

Updated approval letters and current prescribing information for all three affected products are accessible via Drugs@FDA, with the December 2021 update confirming that the required labeling revisions have been incorporated into approved product labeling.

For QA and regulatory leads managing post-approval commitments, the measurable checkpoint is confirmation that distributed labeling, Medication Guides, and any co-promotion materials reflect the revised Boxed Warning language and the narrowed indicated population before the next inspection cycle.

Source: U.S. Food and Drug Administration, Drug Safety and Availability, via FDA.gov; original Drug Safety Communication issued September 1, 2021; updated December 2021.